Phillips-Medisize, a Hudson, Wisconsin-headquartered provider of manufacturing for medical devices, drug delivery, primary pharmaceutical packaging, and commercial products, has invested to expand the capabilities of its 380,000-square-foot facility in Little Rock, Arkansas to include a US Food and Drug Administration (FDA) registered manufacturing center of excellence for connected health and drug-delivery devices.

The construction of purpose-built cleanroom suites as well as FDA registration and ISO 13485 certification are scheduled to be completed for the company’s first production beginning in the second quarter of 2018. This facility establishes a new manufacturing site in Little Rock for Phillips-Medisize’s medical business with capabilities for filling, drug handling, electronics, and connected devices. The company says that the facility will allow it to accommodate large programs requiring extensive assembly and molding operations, in cleanroom and other controlled environments, within a compressed time frame. The facility will have a particular focus on mid- to high-volume diagnostics, medical device and drug-delivery systems that integrate electronics and digital applications.

 The company says the investment aims to combine the knowledge from existing electronics production operations of Molex, the parent company of Phillips-Medisize, with Phillips-Medisize’s platform of drug-delivery and medical-device experience.

This will be Phillips-Medisize’s sixth expansion in the past six years to support growth of its medical contract manufacturing business. In June 2017, the company completed a new 80,000-square-feet facility in Menomonie, Wisconsin. Earlier in 2016, the company opened a 17,000-square-foot clinical and pilot build facility for drug delivery and combination devices in Menomonie, Wisconsin. In November 2015, the company doubled the size of its New Richmond, Wisconsin medical device facility, and in late 2014, it expanded its Finland facility.

Source: Phillips-Medisize